Comprehensive Therapy

, Volume 26, Issue 3, pp 183–189

Osteoporosis: Evaluation and treatment

  • Joan L. Milott
  • Sandra S. Green
  • Marilyn M. Schapia
Original Article

Abstract

Osteoporosis is a common and costly disease. This article discusses the pathophysiology, diagnosis, and treatment of osteoporosis, including hormone replacement, bisphosphonates, calcitonin, raloxifene, and alternative therapies. As our population ages, osteoporosis will become an even more common disease.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporosis International. 1998:(suppl):S7–S80.Google Scholar
  2. 2.
    Melton LJ III Perspectives: how many women have osteoporosis now? J. Bone Miner Res. 1995;10(2):175–177.PubMedCrossRefGoogle Scholar
  3. 3.
    Ross PD Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med. 1996;156:1399–1411.PubMedCrossRefGoogle Scholar
  4. 4.
    American Association of Clinical Endocrinologists. Clinical partice guidelines for the prevention and treatment of post-menopausal osteoporosis. Endocr Pract. 1996;2(2):157–171.Google Scholar
  5. 5.
    Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767–773.PubMedCrossRefGoogle Scholar
  6. 6.
    Melton LJ, Wahner HW, Richelson LS, et al. Osteoporosis and the risk of hip fracture. Am J Epidemiol. 1986;124:254–261.PubMedGoogle Scholar
  7. 7.
    Bone density measurement: a systematic review. J Intern Med. 1997;241((suppl 739):1–60.Google Scholar
  8. 8.
    Jergas M, Genant HK. Current methods and recent advances in the diagnosis of osteoporosis. Arthritis Rheum. 1993;36(12):1649–1662.PubMedCrossRefGoogle Scholar
  9. 9.
    Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hipfracture in women. JAMA. 1990;263:665–668.PubMedCrossRefGoogle Scholar
  10. 10.
    Van Daels P, Burger H, De Laet C, Pois H. Review: ultrasound measurement of bone. Clin. Endocrinol 1996;44:363–369.CrossRefGoogle Scholar
  11. 11.
    Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338(11):736–746.PubMedCrossRefGoogle Scholar
  12. 12.
    Riggs BL, Melton LJ III, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18(suppl):197S-201S.PubMedCrossRefGoogle Scholar
  13. 13.
    Medicare Program. Medicare coverage of and payment for bone mass measurements. Fed Reg. 1998;63(121):34320–34328.Google Scholar
  14. 14.
    Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Ann Intern Med. 1998;129:81–88.PubMedGoogle Scholar
  15. 15.
    Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation of bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995;98:331–335.PubMedCrossRefGoogle Scholar
  16. 16.
    Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med. 1999;130:897–904.PubMedGoogle Scholar
  17. 17.
    NIH Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646–650.CrossRefGoogle Scholar
  18. 18.
    Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9–16.PubMedGoogle Scholar
  19. 19.
    Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1–9.PubMedGoogle Scholar
  20. 20.
    Ettinger, B. Prevention of osteoporosis: treatment of estradiol deficiency. Obstet Gynecol. 1988;72:12S-17S.PubMedGoogle Scholar
  21. 21.
    Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. a randomized, controlled trial. Ann Intern Med. 1999;130:897–904.PubMedGoogle Scholar
  22. 22.
    Grady E, Rubin SM, Petitti DB, et al. Hormone therapy to prevent dsease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037.PubMedGoogle Scholar
  23. 23.
    Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461.PubMedCrossRefGoogle Scholar
  24. 24.
    The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA. 1996;276:1389–1396.CrossRefGoogle Scholar
  25. 25.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613.PubMedCrossRefGoogle Scholar
  26. 26.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–1059.CrossRefGoogle Scholar
  27. 27.
    Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women's health study. JAMA. 1999;281:2091–2097.PubMedCrossRefGoogle Scholar
  28. 28.
    Khovidhunkit W, Shoback D. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130:431–439.PubMedGoogle Scholar
  29. 29.
    Cummings SR, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. [Abstract]. Proceedings of the American Society of Clinical Oncology meeting. 1998:3.Google Scholar
  30. 30.
    Cummings SR, Eckert S, Krueger KA, et al. The effects of raloxifene on risk of breast cancer in postmenpausal women. JAMA 1999;281:2189–2197.PubMedCrossRefGoogle Scholar
  31. 31.
    Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in ∼12,000 postmenopausal women. [Abstract]. Proceedings of the American Society of Clinical Oncology meeting. 1998:466.Google Scholar
  32. 32.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifeneoon bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–1647.PubMedCrossRefGoogle Scholar
  33. 33.
    Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–1451.PubMedCrossRefGoogle Scholar
  34. 34.
    Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–1443.PubMedCrossRefGoogle Scholar
  35. 35.
    Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. JAMA. 1997;277:1159–1164.PubMedCrossRefGoogle Scholar
  36. 36.
    Rico H, Revilla M, Hernández ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int. 1995;56:181–185.PubMedCrossRefGoogle Scholar
  37. 37.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992;305:556–561.PubMedGoogle Scholar
  38. 38.
    Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med. 1995;98:452–58.PubMedCrossRefGoogle Scholar
  39. 39.
    Adelercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med. 1997;29:95–120.Google Scholar
  40. 40.
    Fitzpatrick LA. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal woman. Mayo Clin Proc. 1999;74:601–607.PubMedCrossRefGoogle Scholar
  41. 41.
    Peris P, Guanabens N. Male osteoporosis. Curr Opin Rheumatol. 1996;8:357–364.PubMedCrossRefGoogle Scholar
  42. 42.
    Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of UK Consensus Group. QJM. 1998;91:71–92.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Joan L. Milott
    • 1
  • Sandra S. Green
    • 1
  • Marilyn M. Schapia
    • 1
  1. 1.Medical College of WisconsinWIMilwaukee

Personalised recommendations